PFE Jan 2025 17.500 put
| Previous close | 0.0600 |
| Open | 0.0800 |
| Bid | 0.0500 |
| Ask | 0.1000 |
| Strike | 17.50 |
| Expiry date | 2025-01-17 |
| Day's range | 0.0800 - 0.0800 |
| Contract range | N/A |
| Volume | |
| Open interest | 9.71k |
ReutersPfizer rolls out another cost-cutting program, sets $1.5 billion target by 2027
The cost cuts are the latest move by the company to respond to slumping demand for its COVID-19 products after they powered it to report record revenues in 2021 and 2022. Pfizer's shares were up 2.6% at $29.3 in afternoon trading.
BloombergGSK’s New Vaccine Kept the Boss in Her Job — and an Activist at Bay
(Bloomberg) -- When Elliott Investment Management came calling for the ouster of Emma Walmsley, the chief executive officer of GSK Plc found her remedy in a product almost 60 years in the making.Most Read from BloombergOne Dead After Singapore Air Flight Hit By Severe TurbulenceASML, TSMC Can Disable Chip Machines If China Invades TaiwanHims Debuts $199 Weight-Loss Shots at 85% Discount to WegovyJamie Dimon Says Succession at JPMorgan Is ‘Well on the Way’Tesla Shareholder Group Slams Elon Musk’s
Barrons.comModerna and Novavax Hope for Early Launch of This Year’s Covid-19 Shots, Despite FDA Delay
After disappointing sales for their Covid vaccines last year, drugmakers are hoping for an August rollout of the updated shot.
